JDS Therapeutics, LLC and its subsidiary Nutrition 21, LLC complete $16 Million Series B Round of Institutional Equity Financing

JDS THERAPEUTICS, LLC AND ITS SUBSIDIARY NUTRITION 21, LLC COMPLETE
$16 MILLION SERIES B ROUND OF INSTITUTIONAL EQUITY FINANCING

PURCHASE, N.Y. (October 22, 2015) – JDS Therapeutics, LLC (“JDS”), a privately held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a $16 million Series B institutional equity financing round led by 1315 Capital, a Philadelphia-based investment firm specializing in healthcare.  

Read the full press release here – JDS Therapeutics, $16 Million Series B Round

For more information, visit www.JDStherapeutics.com and www.Nutrition21.com